ZBTB26 Inhibitors
ZBTB26 inhibitors encompass a set of chemical compounds that attenuate the activity of this transcription factor through various direct and indirect mechanisms. Some inhibitors work by disrupting the kinase signaling cascades that are essential for the proper phosphorylation of ZBTB26, a post-translational modification that is crucial for its activation and stability. When these kinases are inhibited, ZBTB26's activity is compromised, leading to its decreased functional presence within the cell. Another class of inhibitors targets the proteasome degradation pathway, specifically by preventing the breakdown of ubiquitinated proteins. This action can inadvertently increase the cellular levels of ubiquitin ligases that mark ZBTB26 for degradation, thus lowering the activity of ZBTB26 by enhancing its removal from the cell.
Additional inhibitors operate by altering the transcriptional regulation of ZBTB26. For instance, some of these compounds inhibit the reading and writing of epigenetic marks such as acetylation, which is crucial for the transcriptional regulation of many genes, including ZBTB26. In doing so, these inhibitors can suppress the expression of ZBTB26, reducing its activity in the cell. Others inhibit histone deacetylases, leading to changes in chromatin structure that could negatively impact ZBTB26 transcription. Furthermore, inhibitors of DNA methyltransferases can induce genome-wide changes in methylation patterns, which may lead to a decrease in ZBTB26 expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that disrupts multiple signaling pathways by inhibiting kinase activities which ZBTB26 may rely on for its phosphorylation and subsequent function. Inhibition of these kinases leads to decreased ZBTB26 activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor which can prevent the degradation of ubiquitinated proteins, potentially increasing the cellular levels of a ubiquitin ligase that targets ZBTB26 for degradation, thus reducing ZBTB26's functional activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A proteasome inhibitor that could stabilize the proteins that mark ZBTB26 for degradation, thereby reducing the levels of functional ZBTB26. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
A BET bromodomain inhibitor that could disrupt the reading of acetylated histone marks, potentially altering the transcriptional landscape in a way that indirectly leads to the downregulation of ZBTB26 expression. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
An inhibitor of eukaryotic protein biosynthesis that could reduce the translation of ZBTB26 mRNA into functional protein, thereby decreasing ZBTB26 activity indirectly through reduced protein synthesis. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that can alter chromatin structure and gene expression, potentially affecting the transcriptional regulation of ZBTB26 and leading to its decreased expression and activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can alter signaling pathways associated with cell survival and proliferation, which may be linked to the stability and activity of ZBTB26, culminating in reduced functionality of the protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can affect protein synthesis and autophagy pathways, potentially altering the stability and turnover of ZBTB26, thereby reducing its functional activity within the cell. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
A modulator of the ubiquitin-proteasome system which can indirectly lead to the destabilization and decreased activity of transcription factors such as ZBTB26 through changes in protein homeostasis. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK1/2 inhibitor that may influence the ERK/MAPK signaling pathway, potentially modifying the post-translational modifications and activity of proteins including ZBTB26, resulting in decreased ZBTB26 activity. | ||||||